Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 20/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20091022 | 0.87 | NFE2L2 (0.46) | NFE2L2 | |
| SCHEMBL20091038 | 0.83 | NFE2L2 (0.43) | NFE2L2 | |
| SCHEMBL20086551 | 0.80 | NFE2L2 (0.51) | NFE2L2 | |
| SCHEMBL18215495 | 0.76 | NFE2L2 (0.51) | NFE2L2 | |
| SCHEMBL20091035 | 0.74 | KCNH2 (0.44) | — | |
| SCHEMBL18215455 | 0.72 | NFE2L2 (0.54) | NFE2L2 | |
| SCHEMBL6758747 | 0.72 | NFE2L2 (0.46) | NFE2L2 | |
| SCHEMBL20091095 | 0.72 | NFE2L2 (0.44) | NFE2L2 | |
| SCHEMBL20090927 | 0.72 | TAS1R3 (0.33) | — | |
| SCHEMBL4615977 | 0.71 | NFE2L2 (0.45) | NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10421751-B2 | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180111922-A1 | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE | LYCERA CORPORATION | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111922-A1 | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE | RORB, RORA, RORC | NFE2L2 707/4885 |
| US-10421751-B2 | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORB, RORA, RORC | NFE2L2 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.